HEM Pharma Inc
376270
Company Profile
Business description
HEM Pharma Inc is a microbiome-specialized healthcare company that operates a customized healthcare business and an LBP (Live Biotherapeutic Products) discovery platform business utilizing PMAS (Personalized Pharmaceutical Metal-Analytical Screening), a gut microbiome simulation technology. Its technology includes PMAS, MBR, Multi-omics, Microbiome, and Metabolome.
Contact
558, Handong-ro, Heunghae-eup
F102ho, 102ho
Gyeongsangbuk-do
Buk-gu
Pohang-si
KORT: +82 18994258
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
94
Stocks News & Analysis
stocks
Steep downgrade for wide moat share
Regulatory pressures squeeze growth outlook for wide moat ASX share.
stocks
The strange effect of the 30% minimum capital gains tax
How the proposed CGT floor creates unexpected outcomes across different incomes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,979.30 | 38.70 | 0.43% |
| CAC 40 | 8,436.24 | 43.63 | -0.51% |
| DAX 40 | 25,465.25 | 352.64 | -1.37% |
| Dow JONES (US) | 52,925.15 | 130.76 | -0.25% |
| FTSE 100 | 10,665.88 | 14.11 | 0.13% |
| HKSE | 24,254.44 | 757.55 | 3.22% |
| NASDAQ | 25,818.69 | 302.47 | -1.16% |
| Nikkei 225 | 66,819.05 | 1,437.91 | -2.11% |
| NZX 50 Index | 13,665.18 | 97.61 | -0.71% |
| S&P 500 | 7,503.85 | 33.58 | -0.45% |
| S&P/ASX 200 | 8,785.10 | 47.50 | 0.54% |
| SSE Composite Index | 3,983.96 | 6.28 | -0.16% |